Pharmacokinetics of moxifloxacin in plasma and tissue of morbidly obese patients

Journal of Antimicrobial Chemotherapy

Volumn 66, Issue 10, 2011, Pages 2330-2335

  Kees, Martin G ^a   Weber, Susanne ^b   Kees, Frieder ^c   Horbach, Thomas ^b,d  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Department of Surgery   (Germany)

^c UNIVERSITY OF REGENSBURG   (Germany)

^d UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

Fluoroquinolones; HPLC; Size descriptor; Volume of distribution

Indexed keywords

MOXIFLOXACIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; BODY HEIGHT; BODY MASS; BODY WEIGHT; CLINICAL ARTICLE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG TISSUE LEVEL; FEMALE; GREATER OMENTUM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; LEAN BODY WEIGHT; MALE; OBESITY; PLASMA CLEARANCE; SMALL INTESTINE; STOMACH BYPASS; SUBCUTANEOUS FAT; TREATMENT DURATION;

ADIPOSE TISSUE; ADULT; ANTI-INFECTIVE AGENTS; AZA COMPOUNDS; BIOLOGICAL AVAILABILITY; BODY COMPOSITION; BODY MASS INDEX; FEMALE; GASTRIC BYPASS; HUMANS; INTESTINE, SMALL; MALE; MIDDLE AGED; OBESITY, MORBID; OMENTUM; QUINOLINES; TISSUE DISTRIBUTION;

EID: 80052878641     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr282     Document Type: Article

References (21)

1. Hanley MJ, Abernethy DR, Greenblatt DJ. Effect of obesity on the pharmacokinetics of drugs in humans. Clin Pharmacokinet 2010; 49: 71-87.
2. Pai MP, Bearden DT. Antimicrobial dosing considerations in obese adult patients. Pharmacotherapy 2007; 27: 1081-91.
3. Wagenlehner FME, Lunz JC, Kees F et al. Serum and prostatic tissue concentrations of moxifloxacin in patients undergoing transurethral resection of the prostate. J Chemother 2006; 18: 485-9.
4. Wagenlehner FME, Kees F, Weidner W et al. Concentrations of moxifloxacin in plasma and urine, and penetration into prostatic fluid and ejaculate, following single oral administration of 400 mg to healthy volunteers. Int J Antimicrob Agents 2008; 31: 21-6.
5. Green B, Duffull SB. What is the best size descriptor to use for pharmacokinetic studies in the obese? Br J Clin Pharmacol 2004; 58: 119-33.
6. Han PY, Duffull SB, Kirkpatrick CMJ et al. Dosing in obesity: a simple solution to a big problem. Clin Pharmacol Ther 2007; 82: 505-8.
7. Stroh C, Birk D, Flade-Kuthe R et al. Results of sleeve gastrectomy- data from a nationwide survey on bariatric surgery in Germany. Obes Surg 2009; 19: 632-40.
8. Balfour JA, Lamb HM. Moxifloxacin: a review of its clinical potential in the management of community-acquired respiratory tract infections. Drugs 2000; 59: 115-39.
9. Stass H, Kubitza D. Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man. J Antimicrob Chemother 1999; 43 Suppl B: 83-90.
10. Esposito S, Noviello S, D'Errico G et al. Concentration of moxifloxacin in plasma and tonsillar tissue after multiple administration in adult patients. J Antimicrob Chemother 2006; 57: 789-92.
11. Breilh D, Jougon J, Djabarouti S et al. Diffusion of oral and intravenous 400 mg once-daily moxifloxacin into lung tissue at pharmacokinetic steady-state. J Chemother 2003; 15: 558-62.
12. Gehanno P, Darantière S, Dubreuil C et al. A prospective, multicentre study of moxifloxacin concentrations in the sinus mucosa tissue of patients undergoing elective surgery of the sinus. J Antimicrob Chemother 2002; 49: 821-6.
13. Wacke R, Förster S, Adam U et al. Penetration of moxifloxacin into the human pancreas following a single intravenous or oral dose. J Antimicrob Chemother 2006; 58: 994-9.
14. Wirtz M, Kleeff J, Swoboda S et al. Moxifloxacin penetration into human gastrointestinal tissues. J Antimicrob Chemother 2004; 53: 875-7.
15. Pai MP, Bordley J, Amsden GW. Plasma pharmacokinetics and tissue penetration of alatrofloxacin in morbidly obese individuals. Clin Drug Invest 2001; 21: 219-24.
16. Falagas ME, Karageorgopoulos DE. Adjustment of dosing of antimicrobial agents for bodyweight in adults. Lancet 2010; 375: 248-51.
17. Allard S, Kinzig M, Boivin G et al. Intravenous ciprofloxacin disposition in obesity. Clin Pharmacol Ther 1993; 54: 368-73.
18. Hollenstein UM, Brunner M, Schmid R et al. Soft tissue concentrations of ciprofloxacin in obese and lean subjects following weight-adjusted dosing. Int J Obes Relat Metab Disord 2001; 25: 354-8.
19. Van Wart S, Phillips L, Ludwig EA et al. Population pharmacokinetics and pharmacodynamics of garenoxacin in patients with community-acquired respiratory tract infections. Antimicrob Agents Chemother 2004; 48: 4766-77.
20. Luque S, Grau S, Valle M et al. Levofloxacin weight-adjusted dosing and pharmacokinetic disposition in a morbidly obese patient. J Antimicrob Chemother 2011; 66: 1653-4.
21. Stass H, Dalhoff A. The integrated use of pharmacokinetic and pharmacodynamic models for the definition of breakpoints. Infection 2005; 33: 29-35.